Based on the documented need for additional education in prostate cancer, the AUA has developed AUA Expert Exchange Podcast: Discussions in Prostate Cancer. 

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from: 

Lantheus Medical Imaging
Novartis Pharmaceuticals Corporation

Biomarkers and Molecular Imaging for Prostate Cancer

AUAUniversity · Biomarkers and Molecular Imaging for Prostate Cancer

  1. Explain the principles of molecular imaging and its application in prostate cancer, including techniques such as PET, MRI, and novel radiotracers.
  2. Evaluate recent advances in molecular imaging technologies and their role in improving the accuracy of prostate cancer diagnosis, staging, and treatment monitoring.
  3. Define and classify different types of biomarkers relevant to prostate cancer, including diagnostic, prognostic, and predictive biomarkers.

CME Available: https://auau.auanet.org/node/41727

Appropriate Use of Genetic Testing (who, what, when and how?)

AUAUniversity · Appropriate Use of Genetic Testing (who, what, when and how?)

  1. Identify the patient populations that should be considered for genetic testing in prostate cancer, based on family history, personal risk factors, and clinical indications.
  2. Integrate genetic testing into clinical practice for prostate cancer, including developing workflows, referral processes, and multidisciplinary collaboration.
  3. Utilize genetic test results to inform personalized treatment plans for prostate cancer patients, including targeted therapies and risk reducing strategies.

CME Available: https://auau.auanet.org/node/41734

Treatment Intensification in Metastatic HSPC

AUAUniversity · Treatment Intensification in Metastatic HSPC

  1. Explain the rationale behind treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), based on its pathophysiology. 
  2. Analyze the rationale and clinical evidence supporting treatment intensification in mHSPC, including potential benefits and risks. 
  3. Select appropriate patients for treatment intensification, considering factors such as disease burden, patient comorbidities, and individual risk profiles. 

CME Available: https://auau.auanet.org/node/41733

Sequencing Of Agents

AUAUniversity · Sequencing Of Agents

  1. Review the latest evidence and clinical guidelines that inform the sequencing of therapeutic agents in metastatic prostate cancer, including data from key clinical trials.
  2. Implement strategies for managing and overcoming resistance to therapy in metastatic prostate cancer, considering the role of sequencing in delaying resistance.
  3. Apply best practices for monitoring treatment response and disease progression in patients undergoing therapy, and adjust sequencing strategies based on these observations.

CME Available: https://auau.auanet.org/node/41735